-
Serum IL-35 Levels Tied to Bone Loss With Rheumatoid Arthritis
drugs
September 27, 2019
Serum interleukin (IL)-35 levels are associated with bone loss and may represent a novel therapeutic target for postmenopausal women with rheumatoid arthritis (RA) ...
-
Antibiotic Use Tied to Higher Risk of Rheumatoid Arthritis
drugs
August 26, 2019
Antibiotic prescriptions are associated with a higher risk of rheumatoid arthritis (RA), according to a study published online in BMC Medicine.
-
Cancer Risks Examined in Rheumatoid Arthritis Patients
drugs
July 25, 2019
Compared with the general population, there is an increased risk for certain cancers in patients with rheumatoid arthritis (RA) in Singapore...
-
Initial Sustained Remission Common in Rheumatoid Arthritis
drugs
July 23, 2019
Six-month sustained remission (SR) is not uncommon in patients with rheumatoid arthritis (RA).
-
Elderly-Onset Rheumatoid Arthritis Ups Bone Erosion Risk
drugs
July 12, 2019
Elderly-Onset Rheumatoid Arthritis Ups Bone Erosion Risk.
-
Phase III programme for the use otilimab for rheumatoid arthritis launched
europeanpharmaceuticalreview
July 08, 2019
A Phase III clinical development programme testing otilimab in patients with RA has begun.
-
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR
drugs
June 19, 2019
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR.
-
Rheumatoid Arthritis Remission Cuts Risk for CV Complications
drugs
June 19, 2019
Rheumatoid Arthritis Remission Cuts Risk for CV Complications.
-
Penicillamine Capsules USP, 250 mg
drugs
June 17, 2019
Penicillamine Capsules USP, 250 mg.
-
EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug
europeanpharmaceuticalreview
May 07, 2019
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis…